Integrated Filing — IndAS



General information about company

Scrip Code 524470
NSE Symbol SYNCOMF
MSEI Symbol NOTLISTED
ISIN INE312C01025
Name of company SYNCOM FORMULATIONS (INDIA) LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 12-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 04-02-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Third quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 12-02-2026   03:00:00
End date and time of board meeting 12-02-2026   04:30:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 11,514.06 35,375.97
Other income 550.09 1,678.61
Total income 12,064.15 37,054.58
2 Expenses
(a) Cost of materials consumed 4,744.91 15,348.84
(b) Purchases of stock-in-trade 1,571.08 4,668.34
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (212.32) 78.91
(d) Employee benefit expense 1,745.26 5,013.78
(e) Finance costs 26.34 77.91
(f) Depreciation, depletion and amortisation expense 136.00 405.00
(f) Other Expenses
1 Other Expenses 1,544.08 4,724.24
Total other expenses 1,544.08 4,724.24
Total expenses 9,555.35 30,317.02
3 Total profit before exceptional items and tax 2,508.80 6,737.56
4 Exceptional items 0.00 4.13
5 Total profit before tax 2,508.80 6,741.69
6 Tax expense
7 Current tax 599.63 1,546.03
8 Deferred tax 18.36 69.30
9 Total tax expenses 617.99 1,615.33
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 1,890.81 5,126.36
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 1,890.81 5,126.36
17 Other comprehensive income net of taxes 236.18 634.44
18 Total Comprehensive Income for the period 2,126.99 5,760.80
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 9,400.00 9,400.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.23 0.61
Diluted earnings (loss) per share from continuing operations 0.23 0.61
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.23 0.61
Diluted earnings (loss) per share from continuing and discontinued operations 0.23 0.61
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-10-2025 01-04-2025
Date of end of reporting period 31-12-2025 31-12-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 PHARMACEUTICALS DRUGS AND FORMULATIONS 11,974.96 36,672.89
2 TRADING OF COMMODITIES 0.0000144 0.00106
3 RENTING OF PROPERTY 0.0008775 0.0027569
Total Segment Revenue 12,064.15 37,054.58
Less: Inter segment revenue
Revenue from operations 12,064.15 37,054.58
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 PHARMACEUTICALS DRUGS AND FORMULATIONS 2,459.03 6,560.21
2 TRADING OF COMMODITIES 0.37 1.72
3 RENTING OF PROPERTY 75.74 257.67
Total Profit before tax 2,535.14 6,819.60
i. Finance cost 26.34 77.91
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 2,508.80 6,741.69
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 PHARMACEUTICALS DRUGS AND FORMULATIONS 45,481.37 45,481.37
2 TRADING OF COMMODITIES 178.80 178.80
3 RENTING OF PROPERTY 3,853.87 3,853.87
Total Segment Asset 49,514.04 49,514.04
Un-allocable Assets 0.00 0.00
Net Segment Asset 49,514.04 49,514.04
4 Segment Liabilities
Segment Liabilities
1 PHARMACEUTICALS DRUGS AND FORMULATIONS 9,448.14 9,448.14
2 TRADING OF COMMODITIES 0.00 0.00
3 RENTING OF PROPERTY 91.97 91.97
Total Segment Liabilities 9,540.11 9,540.11
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 9,540.11 9,540.11
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) 1The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12022026 2These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. 3The company is operating in 3 segments ie a Pharmaceuticals Drugs & Formulations b Trading of Commodities c Renting of Property, particulars of segment wise results are given as required 4As required under Regulation 33 of SEBI LODR Regulations 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 31st December 2025. The report does not have any impact on the above results and notes which needs explanation. 5Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 6The Company currently have three Wholly Owned Subsidiaries namely Synmex Pharma Pvt Ltd Sante Biotech Pvt Ltd and Vincit Biotech International Pvt Ltd 7 The Government of India has notified four Labour Codes namely the Code on Wages 2019 the Industrial Relations Code 2020 the Code on Social Security 2020 and the Occupational Safety Health and Working Conditions Code 2020 with effect from 21 November 2025 which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes but the relevant rules are yet to be notified. Based on the available information as at reporting date no material liability is envisaged in this regard. Financial impact will be reviewed once the relevant rules are notified 8. Syncom has received an intimation regarding rejection of appeal and demand of Rs7089302 towards ineligible Input Tax Credit along with equivalent penalty under Sections 74 sub section 5 and 122 of the CGST Act 2017 total Rs14178604. The Company is obtaining legal advice and proposes to contest the matter by filing an appeal before the appropriate appellate authority.



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-10-2025 01-04-2025
B Date of end of reporting period 31-12-2025 31-12-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit and loss 236.18 634.44
Total Amount of items that will be reclassified to profit and loss 236.18 634.44
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 236.18 634.44